ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - MULTI UNDERLYINGS Stock

Certificat

Z07V5Z

CH1252916130

Market Closed - Swiss Exchange 11:20:01 2024-04-16 EDT
101.5 CHF -0.04% Intraday chart for ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - MULTI UNDERLYINGS
3 months-0.54%
6 months+1.29%

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer ZKB
Z07V5Z
ISINCH1252916130
Date issued 2023-06-26
Strike 273 CHF
Maturity 2024-06-26 (31 Days)
Parity 0.27 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 103.5 CHF
Lowest since issue 98.31 CHF
Spread 5 CHF
Spread %0.49%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
230.4 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.46%
Consensus
  1. Stock Market
  2. Certificates
  3. Z07V5Z Certificat